

Robert Aslanian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11755644/publications.pdf>

Version: 2024-02-01

61
papers

1,196
citations

331670

21
h-index

434195

31
g-index

72
all docs

72
docs citations

72
times ranked

1066
citing authors

#	ARTICLE	IF	CITATIONS
1	Coordination of Histamine H ₃ Receptor Antagonists with Human Adrenal Cytochrome P450 Enzymes. <i>Pharmacology</i> , 2002, 66, 128-135.	2.2	76
2	Synthesis of protected allylamines via palladium-catalyzed amide addition to allylic substrates. <i>Tetrahedron Letters</i> , 1985, 26, 1749-1752.	1.4	74
3	The Total Synthesis of Psymberin. <i>Organic Letters</i> , 2007, 9, 2597-2600.	4.6	56
4	A Novel Pyrrolidine Analog of Histamine as a Potent, Highly Selective Histamine H ₃ Receptor Agonist. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 1593-1599.	6.4	40
5	The Discovery of Potent Antitumor Agent C11-Deoxy-psymberin/irciniastatin A: Total Synthesis and Biology of Advanced Psymberin Analogs. <i>Organic Letters</i> , 2009, 11, 867-870.	4.6	40
6	Pharmacological Characterization of the Novel Histamine H ₃ -Receptor Antagonist N-(3,5-Dichlorophenyl)-N-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 1037-1044.	2.5	39
7	A Useful Pd-Catalyzed Negishi Coupling Approach to Benzylic Sulfonamide Derivatives. <i>Organic Letters</i> , 2008, 10, 2517-2520.	4.6	35
8	Facile route to 1-phosphoryl- and 1-sulfonyl-1,3-dienes via palladium-catalyzed elimination of allylic acetates. <i>Tetrahedron Letters</i> , 1984, 25, 5719-5722.	1.4	34
9	Identification of a dual histamine H ₁ /H ₃ receptor ligand based on the H ₁ antagonist chlorpheniramine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1959-1961.	2.2	34
10	Synthesis and SAR Studies of Fused Oxadiazines as \hat{H}_3 -Secretase Modulators for Treatment of Alzheimer's Disease. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 931-935.	2.8	34
11	The design and synthesis of novel NK ₁ /NK ₂ dual antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 2329-2332.	2.2	33
12	Discovery of a Potent Pyrazolopyridine Series of \hat{H}_3 -Secretase Modulators. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 471-476.	2.8	33
13	Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5150-5154.	2.2	32
14	The Discovery of Pyridone and Pyridazone Heterocycles as \hat{H}_3 -Secretase Modulators. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 184-187.	2.8	32
15	Identification of a novel, orally bioavailable histamine H ₃ receptor antagonist based on the 4-benzyl-(1) Tj ETQq1 1,0,784314,rgBT /Ove	2.2	28
16	The synthesis of substituted biperidine amide compounds as CCR ₃ antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1375-1378.	2.2	28
17	An asymmetric synthesis of the novel H ₃ agonist (+)-(3R,4R)-3-(4-imidazolyl)-4-methylpyrrolidine dihydrochloride (Sch 50971). <i>Tetrahedron: Asymmetry</i> , 2000, 11, 3867-3871.	1.8	27
18	Oxidative entry to \hat{H}_3 -oxy N-acyl amins and hemiaminals: efficient formation of 2-(N-acylaminal) substituted tetrahydropyrans. <i>Tetrahedron Letters</i> , 2007, 48, 1967-1971.	1.4	26

#	ARTICLE	IF	CITATIONS
19	Discovery of fused 5,6-bicyclic heterocycles as β -secretase modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 664-669.	2.2	26
20	New Applications of PhI(OAc) ₂ in Synthesis: Total Synthesis and SAR Development of Potent Antitumor Natural Product Psymberin/Irciniastatin A. <i>Synthesis</i> , 2009, 2009, 2855-2872.	2.3	24
21	The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 466-471.	2.2	23
22	Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 63-68.	2.8	22
23	Discovery of oxazole-based PDE4 inhibitors with picomolar potency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 2594-2597.	2.2	21
24	Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 989-994.	2.2	20
25	Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 171-176.	2.8	20
26	A three-step protocol for lead optimization: Quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 65-70.	2.2	20
27	Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3262-3266.	2.2	20
28	Synthesis of seco-psymberin/irciniastatin A: the discovery of a novel PhI(OAc) ₂ mediated cascade cyclization reaction. <i>Tetrahedron Letters</i> , 2008, 49, 3592-3595.	1.4	18
29	The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: Antagonists versus agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 3020-3023.	2.2	17
30	Steroidal C-21 mercapto derivatives as dissociated steroids: Discovery of an inhaled dissociated steroid. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6343-6347.	2.2	16
31	The Synthesis of Substituted Fluorenes as Novel Non-Imidazole Histamine H3 Inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 2643-2646.	2.2	15
32	Benzimidazole-substituted (3-phenoxypropyl)amines as histamine H3 receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5032-5036.	2.2	15
33	Trans-4-methyl-3-imidazolyl pyrrolidine as a potent, highly selective histamine H3 receptor agonist in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 243-248.	2.2	14
34	4-[(1H-imidazol-4-yl)methyl]benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 2263-2268.	2.2	14
35	Spiro-piperidine azetidinones as potent TRPV1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 783-787.	2.2	14
36	Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 100-105.	2.8	13

#	ARTICLE	IF	CITATIONS
37	Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3609-3613.	2.2	13
38	SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 854-858.	2.2	12
39	Discovery of a series of potent arylthiadiazole H3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 861-864.	2.2	11
40	Manipulation of N,O-Nucleophilicity: Efficient Formation of 4-N-Substituted 2,4-Dihydro-3H-1,2,4-Triazolin-3-ones. <i>Organic Letters</i> , 2004, 6, 4795-4798.	4.6	10
41	Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 395-399.	2.2	10
42	Efficient and regioselective synthesis of pyrimido[5,4-d]pyrimidine-2,4,6,8(1H,3H,5H,7H)-tetraones with diversified substitutions. <i>Tetrahedron Letters</i> , 2012, 53, 7154-7158.	1.4	10
43	Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of Asthma. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 679-684.	2.8	10
44	Two complementary, diversity-driven asymmetric syntheses of a 2,2-disubstituted piperidine NK1 antagonist. <i>Tetrahedron: Asymmetry</i> , 2006, 17, 2596-2598.	1.8	9
45	Discovery of a series of potent, orally active \pm -disubstituted piperidine NK1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6313-6315.	2.2	9
46	The synthesis and structure-activity relationship of 4-benzimidazolyl-piperidinylcarbonyl-piperidine analogs as histamine H3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5004-5008.	2.2	8
47	Efficient synthesis and reaction pathway studies of novel fused morpholine oxadiazolines for use as gamma secretase modulators. <i>Tetrahedron Letters</i> , 2012, 53, 6451-6455.	1.4	8
48	Recent Progress in Histamine H3 Receptor Chemistry. <i>Annual Reports in Medicinal Chemistry</i> , 2004, 39, 57-66.	0.9	7
49	Efficient one-pot formation of 4-N-substituted 2,4-dihydro-3H-1,2,4-triazolin-3-ones from primary amines using N ² -(ethoxymethylene)hydrazinecarboxylic acid methyl ester. <i>Tetrahedron Letters</i> , 2006, 47, 6743-6746.	1.4	6
50	Steroidal C-21 heteroaryl thioethers (Part 2): Discovery of orally bioavailable selective glucocorticoid receptor modulators (dissociated steroids). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1086-1090.	2.2	6
51	Quality by design (QbD) of amide isosteres: 5,5-Disubstituted isoxazolines as potent CRTh2 antagonists with favorable pharmacokinetic and drug-like properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1615-1620.	2.2	6
52	The synthesis of 2,3,6-trisubstituted 1-oxo-1,2-dihydroisoquinolines as potent CRTh 2 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5344-5348.	2.2	6
53	Oxidation of Methyl Heteroaryls with Molecular Oxygen: A Facile Synthesis of 2-[N-(tert-Butoxycarbonyl)amino]-4-pyridinecarbaldehyde. <i>Synthesis</i> , 2007, 2007, 2529-2533.	2.3	4
54	Fused bicycles as arylketone bioisosteres leading to potent, orally active thiadiazole H3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3354-3357.	2.2	4

#	ARTICLE	IF	CITATIONS
55	Steroidal C-21 heteroaryl thioethers. Part 3: Pregn-4-eno-[3,2-c]pyrazole fused A ring modified steroids as selective glucocorticoid receptor modulators (dissociated steroids). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3291-3295.	2.2	4
56	Synthesis of novel anti-inflammatory steroidal macrocycles using ring closing metathesis reaction. <i>Tetrahedron Letters</i> , 2015, 56, 636-638.	1.4	4
57	Structure-Activity relationships of oxime neurokinin antagonists: oxime modifications. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 833-836.	2.2	3
58	Conformation of gem-disubstituted alkylaryl piperidines and their implication in design and synthesis of a conformationally-rigidified NK1 antagonist. <i>Tetrahedron Letters</i> , 2013, 54, 6199-6203.	1.4	3
59	The Synthesis of Substituted Fluorenes as Novel Non-imidazole Histamine H3 Inhibitors.. <i>ChemInform</i> , 2003, 34, no.	0.0	0
60	Identification of a Dual Histamine H1/H3 Receptor Ligand Based on the H1 Antagonist Chlorpheniramine.. <i>ChemInform</i> , 2003, 34, no.	0.0	0
61	Manipulation of N,O-Nucleophilicity: Efficient Formation of 4-N-Substituted 2,4-Dihydro-3H-1,2,4-triazolin-3-ones.. <i>ChemInform</i> , 2005, 36, no.	0.0	0